LCP2 and lung adenocarcinoma: (Yoshihama et al., 2017; Tang et al., 2020) Furthermore, LCP2 was overexpressed in lung adenocarcinoma, diffuse large B-cell lymphoma, and melanoma, and it was associated with poor prognosis.